HA-1 antigen

mismatching of this antigen corresponds to severe graft versus host disease after human leukocyte antigen-identical bone marrow transplantation

Also Known As:

VLHDDLLEA; Val-Leu-His-Asp-Asp-Leu-Leu-Glu-Ala; mHag HA-1; valyl-leucyl-histidyl-aspartyl-aspartyl-leucyl-leucyl-glutamyl-alanine

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

1.	Neoplasms (Cancer) 03/19/2009 - "The mHag HA-1 is aberrantly expressed in cancers of most entities. " 09/01/2008 - "The mHag HA-1 is hematopoiesis restricted, but displays additionally an aberrant expression on solid tumors. " 09/01/2008 - "Here, we show that cytotoxic T lymphocytes (CTLs) solely targeting the human mHag HA-1 are capable of eradicating 3-dimensional human solid tumors in a highly mHag-specific manner in vitro, accompanied by interferon-gamma release. "
2.	Graft vs Host Disease (Graft-Versus-Host Disease) 07/01/2000 - "Disparities in minor histocompatibility antigen (mHAg) HA-1 are involved in the development of acute graft-versus-host disease (GvHD) in adult recipient after HLA-identical sibling donor hematopoietic stem cell transplantation. " 02/13/1998 - "The minor histocompatibility antigen (mHag) HA-1 is the only known mHag for which mismatching is correlated with the development of severe graft versus host disease (GvHD) after human leukocyte antigen-identical bone marrow transplantation. "
3.	Hematologic Neoplasms (Hematological Malignancy) 01/01/2003 - "Thus, the mHag HA-1 can function as an excellent target antigen for immunotherapy of hematological malignancies with no or low risk of GvHD."

1.	Minor Histocompatibility Antigens
2.	Interferon-gamma (Interferon, gamma)
3.	HLA Antigens (Human Leukocyte Antigens)
4.	Antigens

1.	Hematopoietic Stem Cell Transplantation
2.	Bone Marrow Transplantation (Transplantation, Bone Marrow)
3.	Immunotherapy